



January 7, 2023

2022 Annual Report to Shareholders

Cognigenics Inc. has demonstrated (in preclinical animal models) the world's first genetic treatment for mental health disorders. Our breakthrough non-invasive delivery platform, based on our proprietary CRISPR reagents, paves the way for development of a broad range of novel mental health therapeutics. Our first product is a highly effective anxiolytic treatment, with no evidence of side effects. It not only provides long-term treatment of chronic anxiety, but it may potentially cure this debilitating disorder. Ultimately, our research aims to also provide treatments for severe depression, as well as enhanced cognitive abilities in healthy adults.

In 2021, the company began a series of proof-of-concept experiments to test the feasibility of our precision neurogenetic modulator. By end of 2022, we completed three successfully replicated anxiolytic studies, achieving a 36% anxiety reduction in mice behavioral experiments – comparable to Valium – with no evidence of side effects.

We then repeated those studies with other types of behavioral tests, all of which consistently confirmed significant anxiolytic efficacy. Those results were confirmed via immunohistochemical analyses, which showed that only the targeted neuronal receptors were affected.


In 2023, we will enter the pre-production transcriptional engineering phase of our preclinical research by developing and testing RNA versions of our genetic modulator for use in human clinical trials, planned to begin in 2024. These new experiments will support the development of our lead asset, dubbed RCA-101 (RNA Cognitive Advantage), which will be initially indicated for the treatment of chronic severe anxiety in patients who fail to respond to other treatments.

To support these initiatives, in June the company raised \$950,000 in pre-seed funding from Lionheart Ventures and Kilowatt Capital. In October, we added Peter Seidler to spearhead our consumer marketing development, and Tom Lytle was promoted to Vice President-Commercialization to lead our marketing dialogs with strategic partners in the biotech industry.

Thank you for your ongoing support as we continue to make significant progress in realizing this unique genetic technology, which has the potential to transform psychiatric medicine.



John Mee, CEO



Dr. Dean Radin, Chairman